Screening Platforms and Novel Therapeutic Modalities for Drug Discovery
We apply novel approaches to design therapeutics and use phenotypic screening to reach unconventional drug targets.
About
The group was established in 2026 by Dr Roman Fedoryshchak at the University of Bath. Our expertise is built on solid foundations of biochemistry, structural biology, bioinformatics, high-throughput microscopy and cell models of disease.
Our core interests are in developing unique microbial enzymes, the borosin methyltransferases, to improve medchem properties of peptide drugs. We employ phenotypic screening combined with chemoproteomics for unbiased identification of novel targets. And we are particularly interested in phosphatase targets, starting with the PP1–Phactr1 holoenzyme implicated in epilepsy, for which we are building zebrafish and cell models of disease.
Working within the Bath Centre for Drug Discovery and across the University, we collaborate with Chemistry and Life Science groups on compound libraries, disease models and more.
News
- November 2026G-actin FRET biosensor paper published in Journal of Cell Science.
Join us
We are recruiting. See opportunities or get in touch.